TRANSGENIC AND CHIMERIC MOUSE CORE

转基因和嵌合小鼠核心：Director-N。库克 宾夕法尼亚大学的转基因和嵌合小鼠核心设施(TCMF)已经进入 自1992年2月以来在南希·库克博士和斯蒂芬博士的持续共同指导下进行手术 并在Jean Richa博士的日常技术指导下进行。的初始组件 中医药基金是由医学院的财政捐助和 1989年库克和利巴伯博士的实验室，随后分阶段扩大设施， 能力、人员和服务。在过去的五年中，核心产生了广泛的 转基因和基因靶向的小鼠品系已被证明是研究 I型和II型糖尿病、肥胖症、发育期和 多种其他内分泌和新陈代谢紊乱的机制基础。《核心》 实验室位于临床研究地下室的无病原体微生物屏障设施中 大楼。TCMF的主要功能是提供一个集中的实验室，以产生无感染的 携带转基因或个人特别感兴趣的靶向基因改变的小鼠品系 在DERC的项目。将这些技术要求苛刻的程序集中在核心实验室 为每个项目带来更高的效率和显著的成本降低。在当前项目期间 在此期间，中医药基金会提供的服务显著增长，其设施也得到改善和 扩大了。核心的吞吐量潜力大幅增加，这是通过将 核心微量注射实验室的规模，由医学院资助。这一扩张已经 随着服务需求的持续增长，运力翻了一番。此外，核心现在是 敲定用于长期储存胚胎和精子的新的冷冻保存设施。这是对 Core将于2006年夏天开放。这个新配置的安全设施不在现场， 主要核心实验室，由医学院出资建立。其他服务 在目前的资助期内建立的项目包括精子周期保存， 卵胞浆内单精子注射(ICSI)、DNA诊断以及与医学院基因整合 击倒服务。这些服务大大增加了核心对中心成员的效用。 核心将继续保持最高水平的优质服务，并将继续获得新的 技术和专业知识，将服务维持在“最先进的”水平。

TRANSGENIC AND CHIMERIC MOUSE CORE: Director-N. Cooke The Transgenic and Chimeric Mouse Core Facility (TCMF) of the University of Pennsylvania has been in operation since February 1992 under the continuous co-direction of Dr. Nancy Cooke and Dr. Stephen Liebhaber and under the day-to-day technical direction of Dr. Jean Richa. The initial components of the TCMF were assembled from financial contributions of the School of Medicine and resources from the laboratories of Drs. Cooke and Liebhaber in 1989 with subsequent phased expansions in facilities, capabilities, personnel, and services. Over the past five years the Core has generated a wide range of transgenic and gene-targeted mouse lines that have proven to be powerful tools for the study of the molecular biology and physiology of Type I and Type II diabetes, obesity, and developmental and mechanistic bases for a wide variety of other disorders of endocrinology and metabolism. The Core laboratory is located in a pathogen-free microbiologic barrier facility in the basement of the Clinical Research Building. A primary function of the TCMF is to provide a centralized laboratory that will generate infectionfree strains of mice carrying transgenes or targeted genetic alterations of specific interest to individual projects in the DERC. The centralization of these technically demanding procedures in the Core laboratory results in enhanced efficiency and significant cost reduction for each project. During the current project period the TCMF has grown significantly in service offerings and its facilities have been improved and expanded. A major increase in the throughput potential of the Core has been achieved by the doubling in the size of the Core microinjection laboratory, funded by the School of Medicine. This expansion has doubled the capacity in line with the continuing increase in demand for services. In addition, the Core is now finalizing a new Cryopreservation Facility for the long-term storage of embryos and sperm. This addition to the Core will be opening in the summer of 2006. This newly configured, secure facility is off-site from the main Core laboratory, and has been established by funds from the School of Medicine. Additional services that have been established during the current funding period include sperm cyropreservation, intracytoplasmic sperm injection (ICSI), DNA diagnostics, and integration with the School of Medicine gene knock-out service. These services have substantially increased the utility of the Core to Center members. The Core will continue to maintain the highest level of quality service and will continue to acquire new techniques and expertise to maintain services at a 'state-of-the-art' level.